HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarins’ buyback succeeds

This article was originally published in The Rose Sheet

Executive Summary

Financiére FC, a holding company owned by the Courtin-Clarins family, has bought back enough shares to delist Groupe Clarins from the Paris Bourse, French market regulator Autorité des Marchés Financiers (AMF) says in Sept. 24 release. At close of the buyback offer Sept. 16, Financiére FC reportedly owned 96.44% of Clarins' capital and 97.2% of voting rights, clearing 95% threshold required by AMF. Consistent with price set when buyback plan was announced earlier this year, company will purchase remaining 2.21% of Clarins capital for €55.50 per share. Clarins brothers said roughly $1.17 billion would be invested in taking company private, a move that will grant it the stability needed to execute its strategic vision (1"The Rose Sheet" Aug. 11, 2008, p. 5)

You may also be interested in...



Clarins Has Go-Ahead To Buy Out Minority Shareholders, Lowers 2008 Guidance

The Courtin-Clarins family's plan to repurchase all outstanding Groupe Clarins shares and delist from the French stock market has gotten the green light from regulator Autorité des Marchés Financiers (AMF)

Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products

Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.

UsernamePublicRestriction

Register

RS015688

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel